The 14 linked references in paper A. Komarov L., А. КОМАРОВ Л. (2015) “ОЦЕНКА ЧУВСТВИТЕЛЬНОСТИ К КЛОПИДОГРЕЛУ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ // EVALUATION OF SENSITIVITY TO CLOPIDOGREL: THE CURRENT STATE OF THE PROBLEM” / spz:neicon:aterotromboz:y:2015:i:2:p:95-106

  1. 2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal doi:10.1093/eurheartj/ehu278. (the paper at Socionet)
  2. 2013 ACCF/AHA Guideline for the Management of STElevation Myocardial Infarction. JACC,61, 4: 78–140.
  3. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, Volume 64, Issue 24, e139–e228.
  4. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33: 2569–2619 doi:10.1093/eurheartj/ehs215.
  5. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation European Heart Journal doi:10.1093/eurheartj/ehv320.
  6. Aradi D, Storey RF, Komocsi A et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 2014, 35, 209–215 doi:10.1093/eurheartj/eht375.
  7. Hulot J, Collet J, Silvain J et al. Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration: A Systematic Meta-Analysis.J Am Coll Cardiol,2010, Jul 6, 56(2): 134-43. doi: 10.1016/j.jacc.2009.12.071.
  8. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. DOI: 10.1056/NEJMoa1500857.
  9. Aradi D, Komуcsi A, Price MJ et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol,2013. Sep 1. 167(5): 2140–8. doi: 10.1016/j.ijcard.2012.05.100.
  10. Price MJ, Berger PB, Teirstein PS et al. Standard- vs highdose clopidogrel based on platelet function testing after percutaneouscoronary intervention: the GRAVITAS randomized trial. JAMA, 2011. Mar 16, 305(11): 1097-105. doi: 10.1001/jama.2011. 290.
  11. Aradi D, Tornyos A, Pinter T et al. Optimizing P2Y-receptor inhibition in acute coronary syndrome patients based on platelet function testing: impact of prasugrel and highdose clopidogrel. J Am Coll Cardiol, 2014, Mar 25, 63(11): 1061–70. doi: 10.1016/j.jacc.2013.12.023.
  12. Гуськова Е.В., Панченко Е.П., Комаров А.Л., Добровольский А.Б., Самко А.Н. Остаточная реактивность тромбоцитов к АДФ и риск кровотечений у больных стабильной ИБС, получающих двойную антитромбоцитарную терапию в связи с плановым чрескожным коронарным вмешательством.
  13. Karve AM, Seth M, Sharma M. Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am J Cardiol, 2015. Jun 1.и 115(11): 1502-6. doi: 10.1016/j.amjcard. 2015.02.049.
  14. S Gandhi, B Zile, M K. Tan. Increased Uptake of Guideline Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. Canadian Journal of Cardiology, 2014. doi: 10.1016/j.cjca. 2014.09.011.